ArticleBMC infectious diseases2026
Positivity rate of Aspergillus spp. in patients with tuberculosis-like symptoms in Yaoundé, Cameroon and antifungal resistance profile.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary aspergillosis represents a significant public health concern resulting from the proliferation of Aspergillus species within the respiratory tract. This infection is frequently underdiagnosed in comparison to tuberculosis during the management of pulmonary infections, especially among individuals living with HIV. The objective of this study was to determine the positivity rate of Aspergillus spp. from sputum and bronchoalveolar lavage (BAL) samples of patients presenting with tuberculosis-like symptoms at Jamot Hospital in Yaoundé, Cameroon, and to evaluate their antifungal resistance profiles.
methodsA total of 114 samples (104 sputum and 10 bronchoalveolar lavage) were collected for mycological analysis. Data were verified, coded, and analyzed using StatView v5.0 and GraphPad v8.0.2 for Windows. Pearson's chi-square test of independence and multivariate logistic regression models were used to compare percentages, with p < 0.05 considered statistically significant.
resultsAspergillus spp. were detected in 12.3% of samples, with two species identified. Aspergillus niger was predominant (57%0), followed by Aspergillus flavus (29%). A. niger isolates tested (5) exhibited resistance to polyenes, with 80% resistant to amphotericin B and 40% to nystatin, and 20% resistant to the azole fluconazole. All A. niger isolates were susceptible to econazole and clotrimazole. Among the five A. flavus isolates tested, all demonstrated resistance to amphotericin B and fluconazole, 60% to nystatin, and 20% to clotrimazole.
conclusionAspergillus spp. is present in the respiratory tract but often overlooked, and can lead to a misdiagnosis of tuberculosis. Although the very small number of isolates tested, Aspergillus spp. could be also affected to the antimicrobial resistance observed in recent years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.